357 related articles for article (PubMed ID: 12720270)
21. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
[TBL] [Abstract][Full Text] [Related]
23. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
24. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
25. Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children.
Chavhan GB; Mann E; Kamath BM; Babyn PS
Pediatr Radiol; 2014 Oct; 44(10):1266-74. PubMed ID: 24771094
[TBL] [Abstract][Full Text] [Related]
26. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
27. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
[TBL] [Abstract][Full Text] [Related]
28. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas.
Kim YK; Kim CS; Lee YH; Kwak HS; Lee JM
AJR Am J Roentgenol; 2004 May; 182(5):1217-23. PubMed ID: 15100122
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
30. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
31. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging.
Takahama K; Amano Y; Hayashi H; Ishihara M; Kumazaki T
Abdom Imaging; 2003; 28(4):525-30. PubMed ID: 14580096
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
33. Focal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPA.
Kacl GM; Hagspiel KD; Marincek B
Abdom Imaging; 1997; 22(3):264-7. PubMed ID: 9107647
[TBL] [Abstract][Full Text] [Related]
34. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B
Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial.
Zech CJ; Grazioli L; Breuer J; Reiser MF; Schoenberg SO
Invest Radiol; 2008 Jul; 43(7):504-11. PubMed ID: 18580333
[TBL] [Abstract][Full Text] [Related]
36. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
Kim YK; Kim CS; Kwak HS; Lee JM
J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
Wang QJ; Wang Y; Xu X; Xiao H; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
[TBL] [Abstract][Full Text] [Related]
38. Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.
Grazioli L; Bondioni MP; Faccioli N; Gambarini S; Tinti R; Schneider G; Kirchin M
J Gastrointest Cancer; 2010 Dec; 41(4):221-32. PubMed ID: 20405242
[TBL] [Abstract][Full Text] [Related]
39. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
40. MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents.
Chen F; Ward J; Robinson PJ
Magn Reson Imaging; 1999 May; 17(4):549-56. PubMed ID: 10231181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
